Revolutionary Pan-RAS Inhibitors Transform Pancreatic Cancer Treatment Landscape
New pan-RAS inhibitors showing unprecedented 47-58% response rates in pancreatic cancer patients, marking a historic breakthrough after nearly 50 years of research. These targeted therapies could finally bring precision oncology to the deadliest form of cancer.
